Urine Collection Networks Under Pressure: A Wake-Up Call for the Entire Supply Chain

Recent regulatory changes in several Asian countries have tightened requirements for biological waste management and donor privacy, directly impacting urine collection operations – the starting point of all urinary-derived gonadotropins. Collection costs have risen 15-20% over the past two years in major sourcing regions. This trend is not a disadvantage for urinary producers but rather a structural shift that favors established players with compliant, large-scale collection networks. Meanwhile, recombinant manufacturers remain unaffected, highlighting the importance of supply chain diversification for drug formulators. The industry as a whole must monitor this trend as it affects API pricing and long-term availability.